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NF-κBMicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and may contribute to the
development and progression of many infective diseases including human immunodeﬁciency virus 1 (HIV-1)
infection. The Tat protein is fundamental to viral gene expression. In this study, our goal was to investigate the
regulation of a speciﬁc miRNA (known as miR-217) in multinuclear activation of galactosidase indicator
(MAGI) cells and explore the mechanisms by which miR-217 inﬂuenced Tat-induced HIV-1 transactivation
through down-regulation of SIRT1 expression. We showed that miR-217 was up-regulated when Tat was
expressed in multinuclear activation of galactosidase indicator cells. Forced expression of “miR-217 mimics” in-
creased Tat-induced LTR transactivation. In addition, miR-217 signiﬁcantly inhibited SIRT1 protein expression by
acting on the 3′-UTR of the SIRT1 mRNA. In turn, the decrease in SIRT1 protein abundance provoked by miR-217
affected two important types of downstream signaling molecules that were regulated by Tat. Lower expression
of SIRT1 caused by miR-217 enhanced Tat-induced phosphorylation of IKK and p65-NFkB and also exacerbated
the loss of AMPK phosphorylation triggered by Tat. Our results uncover previously unknown links between Tat
and a speciﬁc host cell miRNA that targets SIRT1. We also demonstrate that this regulatory mechanism impinges
on p65-NFkB and AMPK signaling: two important host cell pathways that inﬂuence HIV-1 pathogenesis. Our re-
sults also suggest that strategies to augment SIRT1 protein expression by down-regulation of miR-217 may have
therapeutic beneﬁts to prevent HIV-1 replication.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Efﬁcient inhibition of human immunodeﬁciency virus 1 (HIV-1)
replication by highly active antiretroviral therapy (HAART) has been
shown to signiﬁcantly extend the lifespan of infected individuals.
Current drug regimens typically consist of various combinations of
compounds that target viral proteins (reverse transcriptase, protease,
integrase, gp41) or virus attachment [1–5]. Unfortunately, HAART re-
quires lifelong treatment and cannot eradicate the infection. The
HAART transforms the infection process into a chronic disease. The la-
tent reservoirs stow away the virus in chemical conﬁgurations that
antiretroviral therapy cannot touch [6,7]. Therefore, long-term
HAART frequently results in drug-related toxicities and the occur-
rence of resistant viruses. New therapeutic approaches and new
anti-viral inhibitors are being continuously developed to improve
our ability to control HIV-1 infections [8,9]. Thus, therapies that are
able to eliminate HIV-1 from infected individuals will not only im-
prove and extend current therapeutic options, but may also contrib-
ute to the development of a real cure for AIDS.+86 10 67392780.
rights reserved.The HIV-1 transactivator of transcription (Tat) protein is funda-
mental to viral gene expression in host cells [10]. Tat regulates viral
gene expression by promoting the elongation phase of HIV-1 tran-
scription via binding to a trans-activation response (TAR) RNA ele-
ment containing the HIV-1 long terminal repeat (LTR) sequence that
acts as a viral promoter. By binding to the TAR element, Tat engages
RNA polymerase and other components of the transcription machin-
ery, leading to phosphorylation of the C-terminal domain of RNA po-
lymerase II (RNAPII) by CDK9 and transcription elongation [11]. Tat is
subjected to posttranslational modiﬁcations that recruit host cell pro-
teins to the viral promoter. Tat contains an arginine-rich motif with
lysines at positions 50 and 51 (K50, K51) that binds to the 5′ bulge
in TAR [12,13]. Disassembly of this RNA–protein complex is regulated
by acetylation of Tat-K50. Upon Tat-K50 acetylation by CBP/p300, in-
teractions between Tat and TAR are disrupted and the Tat protein
acetylated at K50 recruits the p300/CBP-associated factor (PCAF) to
RNAPII [14]. After transcription has terminated, Tat is liberated and
K50 is deacetylated by SIRT1. This reversible acetylation allows Tat
to be recycled to TAR for subsequent rounds of HIV transcription [15].
MicroRNAs (miRs) are small (approximately 18–22 nt) non-coding
RNAs that control gene expression [16–18]. MiRs are transcribed from
DNA by RNA polymerase II as hairpin precursors that are further pro-
cessed to mature forms [16–18]. MiRs bind to the 3′-untranslated re-
gion (3′-UTR) of target messenger RNAs (mRNAs) and inhibit their
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translation. Approximately 30% of all human genes are thought to be
regulated by miRs [16–18] and, consistent with this, miRs control
gene expression in diverse biological processes including develop-
ment, differentiation, cell proliferation, and apoptosis. Recent studies
have demonstrated a crucial role for miRs in the regulation of HIV-1
infection [19–22]. A cluster of human miRs consisting of miR-28,
miR-125b, miR-150, miR-223 and miR-382 are highly expressed in
resting CD4+ T lymphocytes where they can target the 3′-UTR of
the HIV-1 RNA, thereby contributing to HIV-1 latency. In addition,
miR-29a targets the messenger RNA encoding the Nef protein of
human HIV-1. Ectopic expression of miR-29a results in a reduction of
Nef protein levels and viral loads. All these different miRs contribute
to suppress HIV-1 viral gene expression [22]. SIRT1 is increasingly rec-
ognized as a critical regulator of stress responses, replicative senes-
cence, inﬂammation, metabolism, and aging. SIRT1 expression is
regulated transcriptionally and post-transcriptionally, and its enzymat-
ic activity is controlled by nicotinamide adenine dinucleotide (NAD+)
levels and interacting proteins [23,24]. In this report, we examined
whether miRNAs directly target the SIRT1 signaling pathway and mod-
ulate its inhibition of HIV-1 transactivation. In the current study, we
demonstrated that Tat induces the expression of miR-217, which
leads to a decrease in the abundance of the SIRT1 protein. Further-
more, we determine the effect of miR-217 on Tat-induced HIV-1 trans-
activation and the downstream NFkB and AMPK signaling pathways.
2. Materials and methods
2.1. Prediction of candidate miRNA binding to the SIRT1 3′UTR
To predict miRNAs potentially binding to the SIRT1 3′UTR se-
quences, we used commonly employed miRNA prediction programs:
TargetScan5.1 (http://www.targetscan.org/), miRBase (http://microrna.
sanger.ac.uk/targets), PicTar (http://pictar.mdc-berlin.de/) and miRanda
(http://microrna.org). Only thosemiRNA target pairs detected by at least
three of the four programswere used for further study. The bioinformat-
ics analysis identiﬁed SIRT1 as a hypothetical target RNA of miR-217, as
identiﬁed by the miRanda, Pictar, and TargetScan algorithms.
2.2. Cell culture and reagents
The HeLa-CD4-LTR-β-galactosidase indicator cell line was MAGI
(multinuclear activation of galactosidase indicator) [25]. MAGI cells
were maintained in DMEM supplemented with 10% FCS, 200 μg/ml
G418, 100 μg/ml hygromycin B, at 37 °C in 5% CO2 and 95% air in hu-
midiﬁed atmosphere. The following polyclonal antibodies: rabbit
anti-p-p65, anti-p65, anti-SIRT1, anti-p-IKK, anti-IKK, and anti-β-
actin were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). ChIP grade rabbit anti-p65, antibodies against phosphorylated
AMPK (Thr172), total AMPK, phosphorylated acetyl-CoA carboxylase
(ACC) (Ser79) and total ACC were from Cell Signaling Technology
Inc (New England Biolabs, Beverly, MA). The secondary antibodies
IR800 anti-rabbit, IR800 anti-goat and IR800 anti-mouse IgG were
obtained from LI-COR Biosciences (Lincoln, Nebraska, USA). The pCI-
Tat plasmid was kindly provided by Prof. Ping-Kun Zhou (Beijing In-
stitute of Radiation Medicine, Beijing). The C30G mutation abolished
Tat transactivation from the HIV-1 promoter but did not affect the
levels of protein expression. All other chemicals were of the highest
commercial grade available.
2.3. Synthesis and transfection of siRNAs, miRNA mimics and
miRNA inhibitors
MiRNA mimics and miRNA inhibitors were designed and synthe-
sized by GenePharmar (Shanghai, China). MiRNA inhibitors were
designed such that all the nucleotides contained a 2′-O-methylmodiﬁcation. Twenty-four hours prior to transfection, cells were plat-
ed into a 6-well plate (Greiner, Germany) at 40–60% conﬂuence.
Transfection of MAGI cells grown in 6-well plates was performed
using 50 nM miR-217 mimics or negative control, 100 nM inhibitor
or negative control, and 1 μl of Lipofectamine 2000 (Invitrogen,
USA), according to the manufacturer's instructions. For miR-217
assay and western blot analysis, cells were harvested for RNA and
protein respectively after 24–48 h.
2.4. Reverse transcriptase-quantitative PCR (RT-qPCR) to determine
miR-217 levels
MAGI cells were transfected with either miR-217 mimics or miR-
217 inhibitors using Lipofectamine 2000. Total RNA was extracted
from the transfected cells with TRIzol (Invitrogen) and 0.4 μg RNA
was used to synthesize cDNA using a ﬁrst strand cDNA synthesis
kit. Following reverse transcription, quantitative PCR (qPCR) was
performed using the MX3000P (Stratagene). The primers used for
Q-PCR are as follows: SIRT1, 5′-AGG AGA CTT GCC TGG TGA AA-
3′(forward)/5′-CAG GGG TGG TTA TTG CAT CT-3′ (reverse); GAPDH,
5′-GCA CCG TCA AGG CTG AGA AC-3′ (forward)/5′-TGG TGA AGA
CGC CAG TGG A-3′ (reverse). Data were normalized according to
the level of GAPDH RNA in each sample [26]. For miRNA real-time
PCR, a commercial Hairpin-it™ miRNAs qPCR Quantiﬁcation Kit
(GenePharma, Shanghai, China) was used. Brieﬂy, 2 μg RNA was
used as template and then reverse transcribed by using a miR-217
speciﬁc RT-primer. The resulting cDNA was further ampliﬁed in the
Q-PCR with a universal reverse primer and a speciﬁc forward primer.
The PCR procedure included pre-denaturation at 95 °C for 5 min, and
then 40 cycles of 95 °C for 10 s, 58 °C for 15 s and 72 °C for 20 s, fol-
lowed by melting curve analysis. U6 was used as an internal control.
At least three independent reactions were performed for each miR-
NAs. The 2−ΔΔCt method was used to determine the miRNA expres-
sion levels relative to the control U6 RNA. Each sample was done in
triplicate.
2.5. Luciferase assays
The SIRT1 3′-UTR sequence spanning 1940 base pairs (bp) was
PCR ampliﬁed with primers (+) TGA TGG AGA TGA TCA AGA GGC
and (−) GAC CCA TGG AGA TGA TCA AGA GGC. This region contains
the miR-217 consensus response element, located between 3740 and
3769 bp downstream of the ATG of sequence AF083106. A mutant se-
quence lacking any complementarity with miR-217 seed sequence
was also cloned in the 3′UTR of the luciferase gene. MAGI cells
were plated in 6-well plates. The next day, 200 ng pMIR-REPORT Lu-
ciferase vector including the 3′-UTR of SIRT1 (with the WT or mutant
miR-217 response element) and precursor miR-217 or a scrambled
oligonucleotide (control miR), were transfected using Lipofectamine
2000 (Invitrogen). After 24 h, luciferase activity was assayed using
an Lmax multiwell luminometer. The total protein concentration
was determined using a Bradford assay (Bio-Rad, USA) by measuring
the absorbance at 595 nm using a spectrophotometer. The luciferase
activity was normalized relative to the total protein content.
2.6. Preparation of nuclear, cytoplasmic extracts and whole cell lysate
Nuclear and cytoplasmic protein extracts were prepared as previ-
ously described with some modiﬁcations [27]. Brieﬂy, cells were
seeded and cultured in 6-well dishes to 90% conﬂuence and treated
with appropriate chemicals as indicated in ﬁgure legends. The cells
were washed once in ice-cold phosphate buffered saline (PBS) and
then harvested by scraping in ice-cold PBS into a 15-ml falcon tube
and collected by centrifugation at 500×g for 5 min. Cells were lysed
with NP-40 lysis buffer (50 mM Tris–HCl, 10 mM NaCl, 5 mM MgCl2,
and 0.5% NP-40, pH8.0) for 10 min on ice. Following lysis, the
Fig. 1. MiR-217 was up-regulated in MAGI cells expressing Tat. MAGI cells were trans-
fected with a pre-miR-217 mimics, control pre-miR mimics, miR-217 inhibitor (As-miR)
or control miR inhibitor with or without 100 nM Tat or Tat mutant (Tatm) expression
plasmid for 48 h. MiR-217 RNA levels were determined by qRT-PCR and normalized to
GAPDH RNA. The data shown were the means of three independent experiments. 1, con-
trol; 2, Tat; 3, pre-miR-217; 4, Tat+pre-miR-217; 5, pre-miR-control; 6, Tat+pre-miR-
control; 7, As-miR-217; 8, Tat+As-miR-217; 9, As-miR-control; 10, Tat+As-miR-control;
11, Tatm. **Pb0.01: comparison of cells with (column 2) or without Tat (column 1).
##Pb0.01: comparison of cells expressing Tat alone (column 2) with cells co-expressing
Tat and miR-217 (column 4) or Tat and a miR-217 inhibitor (column 8).
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500×g for 10 min. The pellet (nuclear fraction) was washed three
times with the same lysis buffer and then resuspended by vortexing
in radioimmune precipitation assay (RIPA) buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxy-
cholate, and 1 μg/ml each of protease inhibitors aprotinin, leupeptin,
and pepstatin). For whole cell lysate, cells were washed with PBS,
harvested and lysed with RIPA buffer. The nuclear, cytoplasmic ex-
tracts and whole cell lysate were cleared of debris by centrifugation
at 15,000×g for 20 min. Protein concentration was estimated using
Bradford protein assay reagents from BioRad (Hercules, CA), and bo-
vine serum albumin (BSA) was used as standard.
2.7. Immunoblot analysis
Cellswere grown on 6-well plates. Following treatment of cells, the
media was aspirated and the cells were washed twice in ice-cold PBS
and lysed in 40 μl of lysis buffer. The samples were then brieﬂy soni-
cated, heated for 5 min at 95 °C, and centrifuged for 5 min. The super-
natants were electrophoresed on SDS-PAGE (8%) gels, and transferred
to nitrocellulose membranes. The nitrocellulose membranes were
blocked with 5% nonfat dry milk in Tris-buffered saline (TBS) for 1 h
at room temperature. The blots were incubated overnight at room
temperature with primary antibodies and then washed six times in
TBS/0.1% Tween 20 prior to 1 h of incubation and visualized with sec-
ondary antibodies using Odyssey Infrared Imaging System (Li-Cor,
Lincoln, NE). All immunoblots were visualized using the Odyssey in-
frared imaging system (LI-COR Biosciences) and secondary antibodies
according to the manufacturer's instructions. When using the infrared
dye-labeled secondary antibody, the membranes were scanned di-
rectly after incubation and the band intensities were quantiﬁed
using the Odyssey infrared imaging system (Li-Cor) [28].
2.8. Chromatin immunoprecipitation (ChIP)
ChIPwas performed as previously described [29]. Fourmicrograms of
anti-p65 was used for immunoprecipitation. A mock immunoprecipita-
tion containing no antibody was performed as a negative control. HIV-1
LTR DNA was detected with real-time PCR using Power SYBR Green
PCR master mix (Applied Biosystems) and the following HIV-1-speciﬁc
primers: HIV-1 5′ LTR forward: 5′-GCCTGGGAGCTCTCTGGCTA-3′;
HIV-1 5′ LTR reverse: 5′-CAACAGACGGGCACACACTACTT-3′. As a con-
trol, GAPDH DNA was detected with GAPDH promoter primers. ChIP re-
sults were analyzed as percent of the total input used for
immunoprecipitation. Percent of the total input was calculated using
the following formula: (copies immunoprecipitated with anti-p65
−copies immunoprecipitated with no antibody)/([copies in the 10%
input×10]−copies immunoprecipitated with no antibody)×100%.
2.9. MAGI cell assay
MAGI cells assays were performed according to the recommended
protocol [30]. Cells were transfected with Tat plasmid for 48 h. Two
days after treatment, the cells were ﬁxed for 5 min with 0.2% glutar-
aldehyde, 1% formaldehyde in phosphate-buffered saline. Cells were
washed twice with phosphate-buffered saline and then staining solu-
tion (4 mM ferrocyanide, 4 mM ferricyanide, 2 mM MgCl2, 0.4 mg/ml
5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal)) was added
and incubated at 37 °C for 1 h. Blue cells were counted by microscopy.
2.10. Statistical analysis
All values were expressed as the means±standard deviation (SD)
of at least three independent experiments. The signiﬁcance of
changes was evaluated using Student's t-test when data consisted of
only two groups or the ANOVA test when three or more groupswere compared. In both cases, differences of Pb0.05 were considered
statistically signiﬁcant.
3. Results
3.1. MiR-217 was up-regulated in Tat-treated magi cells
Our previous study has shown that SIRT1 inhibits Tat-inducedHIV-
1 LTR transactivation [28]. Bioinformatics analyses with the miRanda,
Pictar and TargetScan algorithms identiﬁed SIRT1 as a hypothetical
target RNA of miR-217. To address whether Tat affects miR-217 ex-
pression, we examined the expression of mature miR-217 and U6
RNA in MAGI cells and evaluated the signiﬁcance of differential miR-
217 expression by comparing Ct values of Tat-treated and control
samples. We found that Tat triggered a signiﬁcantly increase in the
level of miR-217: 4.7-fold up-regulation compared with the abun-
dance of miR-217 in control MAGI cells lacking Tat (Fig. 1, columns 1
and 2). While C30G Tat mutant plasmid showed no change in miR-
217 abundance (Fig. 1, columns 1 and 11). Enforced expression of
miR-217 caused by transfection of miR-217 mimics led to an increase
in miR-217 expression (Fig. 1, columns 2 and 4), whereas transfection
of a miR-217 inhibitor led to a decrease in the abundance of miR-217
(Fig. 1, columns 2 and 8). In contrast, cells transfected with inactive
control miRNA mimics or control miRNA inhibitor showed no change
in miR-217 abundance (Fig. 1, columns 2, 6 and 10).
3.2. Tat induced miR-217 expression down-regulation of SIRT1
Bioinformatics analyses with the miRanda, Pictar and TargetScan
algorithms identiﬁed SIRT1 as a hypothetical target RNA of miR-217.
We hypothesized that miR-217 inhibits expression of SIRT1 mRNA
by preventing its translation. To test the hypothesis that miR-217 reg-
ulates the SIRT1 mRNA through the putative miR-217 response ele-
ment, we constructed a reporter vector consisting of a luciferase
cDNA followed by the 3′-UTR of SIRT1. We also constructed a lucifer-
ase reporter vector fused to the SIRT1 3′-UTR, but with a mutated
miR-217 response element. We then transfected the luciferase re-
porter vectors containing either a WT or mutant miR-217 response
element into MAGI cells. We co-transfected the cells with control or
miR-217 mimics and measured luciferase activity. MiR-217 mimics
decreased luciferase activity generated by the reporter vector con-
taining the WT miR-217 response element (Fig. 2A). In contrast,
miR-217 mimics only marginally affected luciferase expression from
the reporter vector containing a mutated miR-217 response element
Fig. 2. Down-regulation of SIRT1 is mediated by Tat induced miR-217. (A). MAGI cells
were co-transfected with miR-217 mimics or a control miR along with a plasmid re-
porter containing a luciferase gene and either the wild-type SIRT1 3′-UTR or a mutant
form of the 3′-UTR. After 48 h, luciferase assays were performed and normalized to the
total protein content. **Pb0.01: comparison of cells expression either miR-217 or a
control miR. (B). MAGI cells were transfected with 100 nM Tat expression plasmid
alone or in combination with either a miR-217 mimics, a control miR, a miR-217 inhib-
itor (As miR-217) or a control miR inhibitor for 48 h. SIRT1 expression was assessed by
western blotting. The signal obtained with a β-actin antibody served as loading control.
Blots are representative of three experiments. 1, control; 2, Tat; 3, pre-miR-217; 4, Tat+
pre-miR-217; 5, pre-miR-control; 6, Tat+pre-miR-control; 7, control; 8, Tat; 9, As-miR-
217; 10, Tat+As-miR-217; 11, As-miR-control; 12, Tat+As-miR-control.
1020 H.-S. Zhang et al. / Biochimica et Biophysica Acta 1823 (2012) 1017–1023(Fig. 2A). Furthermore, miR-217 did not affect the abundance of SIRT1
RNA (data not shown). Taken together, these data suggest that miR-
217 reduces the efﬁciency of SIRT1 mRNA translation, rather than
the abundance of the SIRT1 mRNA, by acting on a response element
located in the SIRT1 3′-UTR.
To addresswhethermiR-217 participates in the regulation of SIRT1
protein expression, we performed in vivo functional studies where
miR-217 was either overexpressed or silenced. Enforced expression
of miR-217 by transfection with miR-217 mimics led to a decrease in
the abundance of the SIRT1 protein in MAGI cells (Fig. 2B, compare
lanes 1 and 3 or lanes 2 and 4), without any change in SIRT1 mRNA
levels (data not shown). In contrast, silencing of miR-217 by transfec-
tion of a miR-217 inhibitor in MAGI cells increased the abundance of
the SIRT1 protein (Fig. 2B, lanes 8–10), without change in the SIRT1
mRNA level (data not shown). In contrast, the controlmiR-217mimics
and the control miR-217 inhibitor, which are both inactive, had no ef-
fect on SIRT1 protein (compare lanes 1, 5 and 11 in Fig. 2B) or SIRT1
mRNA level (data not shown). These data suggest that miR-217 con-
tributes to post-transcriptional regulation of SIRT1 RNA in MAGIFig. 3. miR-217 promotes Tat-induced HIV-1 LTR transactivation in MAGI cells. MAGI
cells were transfected with 100 nM Tat expression plasmid alone or in combination
with either a miR-217 mimics, a control miR, a miR-217 inhibitor (As-miR-217) or a
control miR inhibitor for 48 h. The cells were ﬁxed and stained with X-gal to detect
β-galactosidase activity. Photographs of blue cells were taken 48 h post-infection
using an Olympus microscope and a Kodak digital camera. The data shown are
means±S.D. of six independent experiments. 1, Tat; 2, Tat+pre-miR-217; 3, Tat+
pre-miR-control; 4, Tat+As-miR-217; 5, Tat+As-miR-control. **Pb0.01: comparison
of cells with Tat (column 1).cells, andmiR-217 likely acts by blocking SIRT1 RNA translation, rather
than by promoting cleavage of the SIRT1 RNA.
3.3. MiR-217 affects Tat-induced HIV-1 LTR transactivation in MAGI cells
HeLa cells that express CD4 and are stably transfected with an
HIV-1 long terminal repeat-β-galactosidase reporter DNA (MAGI
cells), were transfected with a Tat expression vector. The number of
β-galactosidase-positive blue cells detected by light microscopy was
counted to determine the efﬁciency of Tat-induced HIV-1 LTR trans-
activation. The role of miR-217 and of its target RNAs in the modula-
tion of Tat-induced HIV-1 LTR transactivation was then investigated
using β-galactosidase assays. Transfection of miR-217 mimics in
MAGI cells caused a 1.84-fold increase in Tat-induced HIV-1 LTR
transactivation (Fig. 3, columns 1 and 2). Consistent with this, a
34.9% decrease in β-galactosidase-positive cells was observed follow-
ing miR-217 silencing by transfection of a miR-217 inhibitor in MAGI
cells (Fig. 3, compare columns 1 and 4). By contrast, neither a control
miR nor a control miR inhibitor affected the number of β-
galactosidase-positive cells observed upon Tat transfection (Fig. 3,Fig. 4. miR-217 contributes to Tat-induced NF-κB activation and AMPK inactivation in
MAGI cells. Cells were transfected with 100 nM Tat expression plasmid alone or in com-
bination with either a miR-217 mimics, a control miR, a miR-217 inhibitor (As-miR-
217) or a control miR inhibitor for 48 h. 1, control; 2, Tat; 3, pre-miR-217; 4, Tat+
pre-miR-217; 5, pre-miR-control; 6, Tat+pre-miR-control; 7, As-miR-217; 8, Tat+
As-miR-217; 9, As-miR-control; 10, Tat+As-miR-control. (A). Western blot analysis
was performed using antibodies against phosphorylated IKK or phosphorylated p65.
As loading control, the blot was probed with antibodies that detect either total IKK or
total p65. Blots are representative of three experiments. (B). Chromatin fragments
from formaldehyde-treated cells were immunoprecipitated with anti-p65 or control
antibodies (non-speciﬁc IgG). Quantitative PCR was performed with primers for an
HIV-1 promoter fragment containing the NF-κB binding site, as outlined in Materials
and Methods. Ampliﬁcation of DNA from the soluble chromatin fraction before immu-
noprecipitation was used as an input control. The y-axis of the graph shows the ratio
of immunoprecipitated HIV-1 promoter DNA relative to the amount of GADPH DNA
in the input fraction. ChIP data are presented as means of three independent biological
experiments, each analyzed in triplicate by qPCR±SDs. **Pb0.01: comparison of ChIP
signals from cells expressing Tat (column 2) versus cells lacking Tat (column 1).
##Pb0.01: comparison of ChIP signals from cells expressing Tat alone (column 2) versus
cells co-expressing Tat and miR-217 (column 4) or cells co-expressing Tat and a miR-
217 inhibitor (column 8). (C). Western blot analysis was performed using antibodies
against phosphorylated AMPK (Thr 172) or phosphorylated ACC (Ser 79). As a loading
control, the blot was probed with antibodies that detect either total AMPK or total
ACC. Blots are representative of three independent experiments.
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hances Tat-induced HIV-1 LTR transactivation in MAGI cells.
3.4. MiR-217 modulates HIV-1 Tat-induced activation of NF-κB and
inactivation of AMPK
In the process of Tat-induced LTR transactivation, SIRT1 activates
the AMPK signaling pathway and represses NF-κB activation [31].
Tat opposes the action of SIRT1 by inactivating AMPK and promoting
NF-κB activation. In turn, the IκB kinase (IKK) and NF-κB signaling
pathway enhances Tat-induced LTR transactivation [27]. To deter-
mine how miR-217 regulates SIRT1 and the IKK/NF-κB pathway, we
investigated whether IKK and NF-κB are activated in MAGI cells trans-
fected with miR-217 mimics or a miR-217 inhibitor. For this purpose,
we assessed whether miR-217, through downregulation of SIRT1,
might activate IKK or NF-κB by increasing their phosphorylation. In-
deed, miR-217 mimics enhanced Tat-induced IKK phosphorylation
and p65/NF-κB phosphorylation (Fig. 4A, compare lanes 2 and 4). In
contrast, forced expression of a miR-217 inhibitor mildly decreased
Tat-induced IKK and p65/NF-κB phosphorylation in MAGI cells
(Fig. 4A, compare lanes 2 and 8).
Previous studies have described a functional NF-κB binding site
in the LTR promoter (−402/−392 nt from the ATG) that is involved
in transcriptional regulation by Tat. In order to address whether
miR-217 affects the binding of NF-κB proteins to LTR promoters,
we performed ChIP assays in MAGI cells expressing Tat. Expression
of Tat increased binding of p65/NF-κB to LTR promoters (Fig. 4B, col-
umns 1 and 2). Minimal binding of p65/NF-κB to LTR promoters was
observed in the absence of Tat, indicating that the recruitment of
p65/NF-κB to the LTR promoter after Tat stimulation was speciﬁc.
Transfection of a miR-217 inhibitor caused a modest decline in the
Tat-stimulated binding of p65/NF-κB to LTR promoters (Fig. 4B, com-
pare columns 2 and 8). In contrast, transfection of miR-217 mimics
potentiated the Tat-stimulated binding of p65/NF-κB to LTR pro-
moters (Fig. 4B, compare columns 2 and 4). The GAPDH gene pro-
moter also contains NF-κB binding sites. However, in contrast to
the HIV-1 LTR promoters, there was no difference in the occupancy
of the GAPDH promoter by p65/NF-κB regardless of whether Tat
was present or not (data not shown).
To investigate potential links between expression of miR-217 and
the pathway downstream of SIRT1, we analyzed the phosphorylation
status of AMPK and acetyl-CoA carboxylase (ACC). ACC is a direct sub-
strate that is phosphorylated by AMPK. Phosphorylation of ACC is
therefore a surrogate marker of active AMPK. Tat triggered a signiﬁ-
cant decrease in the phosphorylation of AMPK and ACC (Fig. 4C,
lanes 1 and 2). Co-expression of Tat with MiR-217mimics led to a fur-
ther downregulation of phosphorylated AMPK and phosphorylated
ACC compared with Tat alone (Fig. 4C, compare lanes 1, 2 and 4). In
striking contrast, co-expression of Tat along with a miR-217 inhibitor
resulted in higher levels of phosphorylated AMPK and phosphorylat-
ed ACC compared with the levels of phosphorylation of AMPK and
ACC observed with Tat alone (Fig. 4C, compare lanes 2 and 8).
4. Discussion
In this study, we showed for the ﬁrst time that miR-217 was sig-
niﬁcantly upregulated by Tat in MAGI cells. Importantly, we showed
that miR-217 negatively regulates SIRT1 expression, suggesting a
role for miR-217 dysregulation in the pathogenesis that results from
Tat-induced HIV-1 transactivation.
MicroRNAs (miRNAs) are small RNAs of 18–25 nucleotides (nt) in
length that play important roles in regulating a variety of biological
processes. Recent studies suggest that cellular miRNAs may serve to
control the replication of viruses in cells [32,33]. If this is truly the
case, one might expect viruses to have evolved the ability to modulate
the expression of cellular miRNAs. Cellular miRNAs can inﬂuence HIVreplication in two ways: direct targeting of HIV-1 RNA sequences or
indirect targeting of RNAs encoding cellular factors involved in HIV
replication [34]. The Nef-derived miRNA, miR-N367, is produced in
human T-cells persistently infected with HIV-1. MiR-N367 can block
HIV-1 Nef expression and long terminal repeat (LTR) transcription,
suggesting that miR-N367 might suppress both Nef function and
HIV-1 transcription through the RNA interference pathway [21].
Two independent research groups discovered a site in the HIV-1 Nef
RNA that is by targeted MiR-29a, which functionally interferes with
HIV replication in human cells [22,35]. In addition, ﬁve other miRNAs
(miR-28, miR-125b, miR-150, miR-223 and miR-382) cooperate to
target the 3′-ends of HIV messenger RNAs leading to proviral latency
in resting CD4+ T cells [36]. In the latter category, Triboulet et al. de-
scribed a role for the miR-17/92 cluster that, through production of
miR-17-5p and miR-20a, targets the PCAFmRNA [37]. PCAF is a cellu-
lar transcription cofactor of the viral Tat protein. Because Tat is re-
quired for productive transcription from the HIV-1 long terminal
repeat (LTR) promoter, suppression of PCAF expression by miR-17-
5p and miR-20a results in reduced viral transcription and replication
[37]. Another example of a miR-regulated factor linked to HIV-1 rep-
lication is the miR-198-dependent repression of the Tat co-factor Cy-
clin T1, which prevents HIV from thriving in monocytes [38]. A
possible regulatory circuit at the peak of HIV-1 replication involves
downregulation of microRNA-29, expression of Nef, the apoptosis of
host CD4 cells and upregulation of microRNA-223 [39]. Replication
of the integrated HIV-1 is dependent on cellular co-factor Cyclin T1,
miR-27b as a novel regulator of Cyclin T1 protein levels and HIV-1
replication, while miR-29b, miR-223, and miR-150 may indirectly
regulate Cyclin T1 [40]. HIV-1 Tat protein increases the levels of
miR-34a and promotes neuronal dysfunction [41]. Though Tat targets
a nascent TAR RNA for activation, but there were no TAR-like ele-
ments in the miR217 promoter/5′ leader. In addition to its binding
to TAR RNA, Tat is a robust transactivating protein that induces a va-
riety of effects by altering the expression levels of cellular and viral
genes, including microRNA expression. In this study we showed, for
the ﬁrst time, that miR-217 is signiﬁcantly up-regulated in MAGI
cells expressing Tat. In addition, we demonstrated that MiR-217 en-
hances Tat-induced HIV-1 transactivation, suggesting that miR-217
plays a positive role in HIV-1 replication.
Viral transactivation requires Tat to interact with many different
cellular proteins and even transiently bind to viral RNA. Tat accom-
plishes this through post-translational modiﬁcations such as phos-
phorylation, methylation, and acetylation. The recruitment of HATs
and HDACs to the HIV-1 LTR mediated by Tat facilitates viral tran-
scription [12,14]. Tat forms a complex with both CBP/p300 and
PCAF, which attracts HATs to the viral promoter and nearby nucleo-
somes to activate transcription [42]. Tat recruits a protein kinase
complex that facilitates processive transcription by phosphorylating
residues in the C-terminal tail of the large subunit of RNA polymerase
II [43,44]. This activity is promoted by CBP/p300-mediated acetyla-
tion of Tat. However, Tat also interacts with the class III deacetylase
sirtuin 1 (SIRT1). Binding of Tat to SIRT1 has two effects. First, SIRT1
deacetylates and inactivates Tat [15]. Second, Tat inhibits the SIRT1-
mediated deacetylation of the p65 subunit of NF-κB, thus promoting
the transcriptional activity of NF-κB [45]. The presence of Tat induces
the acetylation of histones H3 and H4 by CBP/p300 and PCAF to favor
transcriptional activation of the HIV-1 LTR [43,44]. Lysine 50 in Tat is
deacetylated by SIRT1 [15]. The balance between acetylation and dea-
cetylation of speciﬁc factors is regulated at an additional level. SIRT1
directly interacts with PCAF and p300 to promote their deacetylation
and enzymatic inactivation. Recruitment of SIRT1 to its targets brings
it in close proximity to HATs and allows SIRT1-mediated deacetyla-
tion of p300, CBP and PCAF. The balance of HAT and HDAC/SIRT1 ac-
tivities and their dysregulation in HIV-1 infection alter the
expression, stability and localization of target proteins. Data from
previous studies showed that miR-217 directly inhibits SIRT1, a
1022 H.-S. Zhang et al. / Biochimica et Biophysica Acta 1823 (2012) 1017–1023critical regulator of stress responses, replicative senescence, inﬂam-
mation, metabolism, and aging. We found that miR-217 inhibits Tat-
induced NF-κB activation (as monitored by phosphorylation of p65)
and recruitment of NF-κB to the HIV-1 promoter. These results sug-
gest that up-regulation of miR-217 may inﬂuence Tat-induced HIV-
1 transactivation by inactivation of NF-κB signaling pathway through
down-regulation of SIRT1 expression.
Unlike other deacetylases, sirtuins require nicotinamide adenine
dinucleotide (NAD+) as a co-substrate. During the course of the reac-
tion, sirtuins hydrolyze the NAD+ co-substrate into O-acetyl-ADP ri-
bose and nicotinamide. Thus, the regulation of Tat's transcriptional
activity by SIRT1 connects HIV transcription with NAD+ levels and,
therefore, the metabolic state of the cell [15,45]. Both SIRT1 and
AMPK are activated during the cellular response to nutrient depriva-
tion and act in a concerted manner under several physiological condi-
tions [46]. Consistent with this, the expression of Tat in MAGI cells not
only leads to a decrease in SIRT1 abundance, but also causes a loss of
Thr172 phosphorylation in the α-subunit of AMPK: Thr172 is located
in the activation loop of AMPK and, therefore, Thr172 phosphoryla-
tion is necessary for AMPK activity [31]. This Tat-induced inhibition
of AMPK can be enhanced by treatment with the selective AMPK in-
hibitor compound C (also known as dorsomorphin) [31] or overcome
by treatment with the AMPK activator AICAR. Activation of β-
galactosidase expression by Tat was inhibited by AICAR and stimulat-
ed by compound C, suggesting that AMPK negatively regulates Tat
transactivation. Further experiments using a SIRT1‐speciﬁc siRNA, a
SIRT1 inhibitor (nicotinamide) or an activator (resveratrol) suggested
that Tat mediates its effects on AMPK via inhibition of SIRT1. Our
study demonstrated that up-regulation of miR-217 inﬂuences Tat-
induced HIV-1 transactivation by inactivation of the AMPK signaling
pathway through down-regulation of SIRT1 expression.
5. Conclusions
We found that miR-217 is induced by Tat and, therefore, likely
plays a role in the pathogenesis caused by HIV-1 gene expression
and replication. We performed in silico studies to predict downstream
targets of miR-217 and used functional assays to conﬁrm that miR-
217 downregulated SIRT1 by directly acting on the SIRT1 mRNA.
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